文献速递中医内科中药与中成药合理使用中医康复

乳腺癌术后睡眠障碍的药物管理

Pharmacologic management of postoperative sleep disturbance in breast cancer.
PubMed 文献 · Front Pharmacol · 2026-07-29

本文为叙述性综述,总结乳腺癌术后睡眠障碍(PSD)的药物管理证据。文章提出基于表型的药物管理框架,强调根据症状特征选择药物并关注乳腺癌特异性安全考量,同时指出CBT-I应作为首选的辅助策略。

要点

  • 根据症状表型选择药物:夜间高唤醒用短程催眠药,昼夜节律紊乱用褪黑素类,疼痛为主用加巴喷丁类。
  • 药物选择需评估镇静负荷、阿片联用呼吸风险、次日认知影响及内分泌治疗背景。
  • 服用他莫昔芬者应避免强CYP2D6抑制剂。

核心结论

  • 乳腺癌术后睡眠障碍是临床有意义的手术后恢复和生存期照护组成部分,基于表型的药物管理框架可能临床有用但尚属概念性。

研究设计与样本

  • 叙述性综述,总结乳腺癌术后睡眠障碍的现有证据,重点为药物管理、治疗定位和乳腺癌特异性安全考量。

主要发现

  • 短程催眠药可考虑用于以夜间高唤醒为特征的急性失眠,褪黑素及褪黑素受体激动剂可能特别适用于昼夜节律紊乱为主的情况。
  • 加巴喷丁类药物和多模式镇痛策略可能更适合疼痛为主或混合症状表现。
  • CBT-I最好定位为首选辅助策略,尤其用于持续症状或药物降阶期间;亮光疗法、运动康复、正念干预和针灸可能提供选择性支持获益,但角色为补充而非主要。

关键数值与推荐

  • 药物选择应考虑累积镇静负担、与同时使用阿片类药物相关的呼吸风险、次日认知不良反应及内分泌治疗背景。
  • 接受他莫昔芬治疗的患者应避免使用强CYP2D6抑制剂。

临床怎么用

  • 临床可根据患者症状表型(夜间高唤醒、昼夜节律紊乱、疼痛为主或混合)选择相应药物类别。
  • 处方药物时需评估镇静累积、阿片联用呼吸风险、次日认知影响,并核查内分泌治疗用药(他莫昔芬避免强CYP2D6抑制剂)。
  • 将CBT-I作为首选的辅助策略,尤其用于持续症状或药物降阶阶段。

局限性

  • 基于表型的药物管理框架仍为概念性,尚未在乳腺癌术后人群中进行前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Postoperative sleep disturbance (PSD) is a common yet underrecognized complication after breast cancer surgery and is associated with pain, fatigue, affective symptoms, impaired quality of life, and delayed postoperative recovery. Its management remains challenging because symptom presentations are clinically heterogeneous, and treatment decisions must balance therapeutic efficacy with safety within the broader context of breast cancer care and survivorship. This narrative review summarizes the current evidence on PSD after breast cancer surgery, with particular emphasis on pharmacologic management, therapeutic positioning, and breast cancer-specific safety considerations. Available evidence suggests that a phenotype-guided pharmacologic management framework may be clinically useful, although this approach remains conceptual and has not yet been prospectively validated in postoperative breast cancer populations. Short-course hypnotics may be considered for acute insomnia characterized by prominent nocturnal hyperarousal, whereas melatonin and melatonin receptor agonists may be particularly relevant when circadian disruption predominates. In contrast, gabapentinoids and multimodal analgesic strategies may be more appropriate for pain-dominant or mixed symptom presentations. Across drug classes, treatment selection should account for cumulative sedative burden, respiratory risk associated with concurrent opioid use, next-day cognitive adverse effects, and endocrine therapy context, including avoidance of strong CYP2D6 inhibitors in patients receiving tamoxifen. Among non-pharmacologic interventions, cognitive behavioral therapy for insomnia (CBT-I) is best positioned as the leading adjunctive strategy, particularly for persistent symptoms or during medication de-escalation. Bright light therapy, exercise-based rehabilitation, mindfulness-based interventions, and acupuncture may provide selective supportive benefits in appropriately selected patients, although their roles are generally complementary rather than primary. Overall, PSD after breast cancer surgery should be recognized as a clinically meaningful component of postoperative recovery and survivorship care. Future studies should prioritize standardized sleep outcomes, objective monitoring where feasible, clearer phenotype definition, and integrated efficacy-safety assessment to support more individualized and mechanism-informed management.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bu F, Zeng S, Liu Q, et al. Pharmacologic management of postoperative sleep disturbance in breast cancer. Front Pharmacol. 2026. PMID: 42591116. doi:10.3389/fphar.2026.1844297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。